Tudor Investment Corp ET AL Buys New Position in Abivax SA Sponsored ADR $ABVX

Key Points

• Tudor Investment Corp initiated a new position in Abivax, buying 32,883 shares worth about $2.79 million in Q3, and institutional investors now own roughly 47.91% of the company.
• Abivax shares recently traded near $126.14 (52-week range $5.49–$148.83) with a market cap of $9.99 billion, and the company reported a ($1.20) EPS loss for the most recent quarter while analysts expect about -2.83 EPS for the year.
• Analyst sentiment is mostly positive — one Strong Buy and thirteen Buy ratings vs. one Sell — with an average target of $137.15, and firms like Morgan Stanley and Barclays have recently raised their price targets to $145 and $148, respectively.

Tudor Investment Corp ET AL bought a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 32,883 shares of the company's stock, valued at approximately $2,792,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock valued at $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp acquired a new position in Abivax during the third quarter worth about $36,000. Hantz Financial Services Inc. acquired a new stake in shares of Abivax in the 3rd quarter worth approximately $52,000. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Abivax in the third quarter valued at $76,000. Finally, Covestor Ltd purchased a new position in Abivax during the 3rd quarter valued at about $96,000. Hedge funds and other institutional investors own 47.91% of the company's stock.

Abivax Stock Up 0.4%

Shares of NASDAQ ABVX opened at $126.14 on Friday. The stock's 50 day moving average price is $118.21 and its two-hundred day moving average price is $113.28. Abivax SA Sponsored ADR has a 52-week low of $5.49 and a 52-week high of $148.83. The stock has a market capitalization of $9.99 billion, a P/E ratio of -23.49 and a beta of 1.68.

Abivax (NASDAQ:ABVX - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The business had revenue of $0.52 million for the quarter. On average, analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Analyst Ratings Changes

ABVX has been the subject of a number of analyst reports. Citigroup reissued a "market outperform" rating on shares of Abivax in a report on Thursday, January 8th. Morgan Stanley increased their price target on shares of Abivax from $101.00 to $145.00 and gave the stock an "overweight" rating in a research note on Friday, January 9th. Barclays lifted their price objective on Abivax from $142.00 to $148.00 and gave the company an "overweight" rating in a research note on Tuesday, March 24th. Citizens Jmp upped their price target on shares of Abivax from $114.00 to $131.00 and gave the stock a "market outperform" rating in a research report on Tuesday, December 16th. Finally, Wall Street Zen downgraded shares of Abivax from a "hold" rating to a "sell" rating in a research report on Saturday, December 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $137.15.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.